# E-cigarette use, measured for the first time, emerged as a major concern at 17 percent, indicating a clear shift from ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

A recent study suggests that liraglutide, a drug similar to Ozempic, may reduce migraine frequency in obese individuals with ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

The Obesity Drug Development Summit Europe is your perfect platform to be in a prime position to be at the forefront of this ...

The drug works by acting on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Obesity remains one of the greatest health challenges worldwide, leading to diabetes, heart disease, and increased healthcare ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...